Back in March, we alerted you to a draft policy from Blue Cross Blue Shield of Tennessee that classified PNS devices for the treatment of acute and chronic pain as investigational. BCBS of TN claimed in that policy that “[o]verall, there is a lack of literature evaluating long-term efficacy and adverse events associated with implantable PNS devices.” You can view our previous commentary here.
0 Comments
|
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2024
Categories |
Copyright © 2024 North American Neuromodulation Society. All Rights Reserved.
Contact Us | Privacy Policy | Refund Policy | Sitemap | Sign Up for Email |
__________________________________
111 North Wabash Avenue Suite 100-3653 Chicago, IL 60602 __________________________________
Phone: (773) 648-7845 Fax: (773) 648-7847 |